{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05199688",
            "orgStudyIdInfo": {
                "id": "WN41733"
            },
            "secondaryIdInfos": [
                {
                    "id": "2019-004092-39",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)",
            "officialTitle": "A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)",
            "acronym": "SAkuraSun",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-pharmacokinetics-efficacy-safety-tolerability-and-pharmacodynamics-of-satralizumab-in-pediatric-patients-with-aquaporin-antibody-positive-neuromyelitis-optica-spectrum-disorder-nmosd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-09-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-12-03",
            "studyFirstSubmitQcDate": "2022-01-05",
            "studyFirstPostDateStruct": {
                "date": "2022-01-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study."
        },
        "conditionsModule": {
            "conditions": [
                "Neuromyelitis Optica Spectrum Disorder",
                "NMOSD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 8,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Participants with body weight \u226510kg to <20kg",
                    "type": "EXPERIMENTAL",
                    "description": "Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients",
                    "interventionNames": [
                        "Drug: Satralizumab"
                    ]
                },
                {
                    "label": "Cohort 2 Participants with body weight \u226520kg to <40kg",
                    "type": "EXPERIMENTAL",
                    "description": "Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.",
                    "interventionNames": [
                        "Drug: Satralizumab"
                    ]
                },
                {
                    "label": "Cohort 3 Participants with body weight \u226540kg",
                    "type": "EXPERIMENTAL",
                    "description": "Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.",
                    "interventionNames": [
                        "Drug: Satralizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Satralizumab",
                    "description": "Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.",
                    "armGroupLabels": [
                        "Cohort 1: Participants with body weight \u226510kg to <20kg",
                        "Cohort 2 Participants with body weight \u226520kg to <40kg",
                        "Cohort 3 Participants with body weight \u226540kg"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Summary of observed serum concentration [Cthrough] of satralizumab",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Apparent clearance [CL/F] of satralizumab",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Apparent volume of distribution [V/F] of satralizumab",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Area under the concentration-time curve [AUC] of satralizumab",
                    "timeFrame": "Week 48"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of relapse-free patients by Week 48",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Annualized relapse rate (ARR), defined as the average number of relapses for each year of the study",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Time to first relapse (TFR) after randomization, defined as the time from randomization until the first occurrence of relapse, as determined by the investigator",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Time to relapse requiring rescue therapy",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Change from baseline in Expanded Disability Status Scale (EDSS) at Weeks 24 and 48",
                    "timeFrame": "Baseline, Week 24, Week 48"
                },
                {
                    "measure": "Change from baseline in visual acuity at Weeks 24 and 48",
                    "timeFrame": "Baseline, Week 24, Week 48"
                },
                {
                    "measure": "Change from baseline in FACES Pain Rating Scale at Weeks 24 and 48",
                    "timeFrame": "Baseline, Week 24, Week 48"
                },
                {
                    "measure": "Change from baseline in EuroQol 5-Dimension, Youth (EQ-5D-Y) score and its proxy at Weeks 24 and 48",
                    "timeFrame": "Baseline, Week 24, Week 48"
                },
                {
                    "measure": "Incidence and severity of adverse events",
                    "timeFrame": "Week 48"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age at screening 2-11 years, inclusive\n* Body weight at screening \\>=10 kg\n* For female patients of childbearing potential (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of contraception\n* Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening\n* Neurological stability for \\>=30 days prior to both screening and baseline\n* Expanded Disability Status Scale (EDSS) 0 to 6.5\n* For patients receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Evidence of other demyelinating disease mimicking NMOSD\n* Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline\n* Evidence of chronic active hepatitis B or C\n* Evidence of untreated latent or active tuberculosis (TB)\n* Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline\n* History of severe allergic reaction to a biologic agent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "11 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: WN41733 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S.)",
                    "email": "global-roche-genentech-trials@gene.com"
                },
                {
                    "name": "Global Medical Information",
                    "role": "CONTACT",
                    "email": "global.medical_information@roche.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital Colorado.",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218-1007",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Hospital de Pediatr\u00eda S.A.M.I.C.- Prof. Dr. Juan P. Garrahan",
                    "status": "RECRUITING",
                    "city": "Ciudad Autonoma Buenos Aires",
                    "zip": "C1249ABN",
                    "country": "Argentina",
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Clinica Universitaria Reina Fabiola",
                    "status": "RECRUITING",
                    "city": "Cordoba",
                    "zip": "X5004FHP",
                    "country": "Argentina",
                    "geoPoint": {
                        "lat": -31.4135,
                        "lon": -64.18105
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire de Bic\u00eatre",
                    "status": "RECRUITING",
                    "city": "Le Kremlin-bic\u00eatre",
                    "zip": "94275",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.81471,
                        "lon": 2.36073
                    }
                },
                {
                    "facility": "IRCCS Ospedale Pediatrico Bambino Ges\u00f9 - INCIPIT - PIN",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "state": "Lazio",
                    "zip": "00165",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Fondazione Istituto Neurologico Mondino IRCCS",
                    "status": "RECRUITING",
                    "city": "Pavia",
                    "state": "Lombardia",
                    "zip": "27100",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.19205,
                        "lon": 9.15917
                    }
                },
                {
                    "facility": "Uniwersyteckie Centrum Kliniczne",
                    "status": "RECRUITING",
                    "city": "Gdansk",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 54.35205,
                        "lon": 18.64637
                    }
                },
                {
                    "facility": "Great Ormond Street Hospital for Children",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "WC1N 3JH",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Mexico",
                "Ukraine"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009471",
                    "term": "Neuromyelitis Optica"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009188",
                    "term": "Myelitis, Transverse"
                },
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009902",
                    "term": "Optic Neuritis"
                },
                {
                    "id": "D000009901",
                    "term": "Optic Nerve Diseases"
                },
                {
                    "id": "D000003389",
                    "term": "Cranial Nerve Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12414",
                    "name": "Neuromyelitis Optica",
                    "asFound": "Neuromyelitis Optica",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12142",
                    "name": "Myelitis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12143",
                    "name": "Myelitis, Transverse",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M12387",
                    "name": "Neuritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12833",
                    "name": "Optic Neuritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12832",
                    "name": "Optic Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6605",
                    "name": "Cranial Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4103",
                    "name": "Neuromyelitis Optica Spectrum Disorder",
                    "asFound": "Neuromyelitis Optica Spectrum Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3988",
                    "name": "Myelitis",
                    "relevance": "LOW"
                },
                {
                    "id": "T4263",
                    "name": "Optic Neuritis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}